BARCELONA, Spain and CAMBRIDGE, MA, USA I July 05, 2016 I Oryzon Genomics (ISIN Code: ES0167733015) (MAD: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has designated its next drug, ORY-3001, for preclinical development. This is the third drug candidate produced by the Company, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of, yet undisclosed, non-oncological conditions.
Oryzon has a highly competitive and productive Epigenetics Platform, centered around the development of LSD1 inhibitors, with a first drug currently in Phase IIA in acute leukemia that validates the platform scientifically and clinically. This Platform has so far produced two compounds in clinical development with multiple indication opportunities for both drugs
LSD1 is an enzyme that removes methyl marks from lysine 4 of histone H3, a nucleosomal protein involved in the organization and control of accessibility of DNA for transcription. Modifications of these histone marks are associated with changes in gene transcription. Modulation of LSD1 activity can be used to change the transcriptional balance in cells, and LSD1 has been suggested to be a potential target for certain cancer types, for neurodegenerative disorders, for treatment of viral infections, and other indications.
Oryzon’s LSD1 drugs are pioneering the Histone demethylases field with its forerunner oncologic drug that was licensed to Roche in 2014 and a second program in Phase I in neurodegenerative disorders. The company will focus its therapeutic efforts with this third drug preferentially in non-oncological orphan indications.
ORY-3001 is an enantiomerically pure, potent and selective compound with good pharmacological properties, orally bioavailable, with optimal PK, safety and selectivity profile. After successful completion of regulatory toxicology studies, the company expects to move ORY-3001 into Clinical Phase I/IIa studies in the H2 of 2017.
About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.
SOURCE: Oryzon
Post Views: 143
BARCELONA, Spain and CAMBRIDGE, MA, USA I July 05, 2016 I Oryzon Genomics (ISIN Code: ES0167733015) (MAD: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has designated its next drug, ORY-3001, for preclinical development. This is the third drug candidate produced by the Company, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of, yet undisclosed, non-oncological conditions.
Oryzon has a highly competitive and productive Epigenetics Platform, centered around the development of LSD1 inhibitors, with a first drug currently in Phase IIA in acute leukemia that validates the platform scientifically and clinically. This Platform has so far produced two compounds in clinical development with multiple indication opportunities for both drugs
LSD1 is an enzyme that removes methyl marks from lysine 4 of histone H3, a nucleosomal protein involved in the organization and control of accessibility of DNA for transcription. Modifications of these histone marks are associated with changes in gene transcription. Modulation of LSD1 activity can be used to change the transcriptional balance in cells, and LSD1 has been suggested to be a potential target for certain cancer types, for neurodegenerative disorders, for treatment of viral infections, and other indications.
Oryzon’s LSD1 drugs are pioneering the Histone demethylases field with its forerunner oncologic drug that was licensed to Roche in 2014 and a second program in Phase I in neurodegenerative disorders. The company will focus its therapeutic efforts with this third drug preferentially in non-oncological orphan indications.
ORY-3001 is an enantiomerically pure, potent and selective compound with good pharmacological properties, orally bioavailable, with optimal PK, safety and selectivity profile. After successful completion of regulatory toxicology studies, the company expects to move ORY-3001 into Clinical Phase I/IIa studies in the H2 of 2017.
About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.
SOURCE: Oryzon
Post Views: 143
